$SANA
Sana Biotechnology, Inc.
CIK:0001770121|SEC Filings
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands |
3 Months Ended | 6 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|||||
| Operating expenses: | ||||||||
| Research and development | $ 30,729,000 | $ 29,761,000 | $ 59,448,000 | $ 66,950,000 | ||||
| Research and development related success payments and contingent consideration | 23,913,000 | 10,262,000 | [1] | 32,346,000 | 12,219,000 | [1] | ||
| General and administrative | 10,778,000 | 10,341,000 | 22,240,000 | 21,825,000 | ||||
| Impairment of long-lived assets | 0 | 44,611,000 | [1] | 0 | 44,611,000 | [1] | ||
| Total operating expenses | 65,420,000 | 94,975,000 | [1] | 114,034,000 | 145,605,000 | [1] | ||
| Loss from operations | (65,420,000) | (94,975,000) | [1] | (114,034,000) | (145,605,000) | [1] | ||
| Interest income, net | 1,129,000 | 577,000 | [1] | 2,080,000 | 1,569,000 | [1] | ||
| Other income, net | 656,000 | 598,000 | [1] | 1,109,000 | 847,000 | [1] | ||
| Net loss | $ (63,635,000) | $ (93,800,000) | [1] | $ (110,845,000) | $ (143,189,000) | [1] | ||
| Net loss per common share - basic | $ (0.22) | $ (0.39) | $ (0.39) | $ (0.6) | ||||
| Net loss per common share - diluted | $ (0.22) | $ (0.39) | $ (0.39) | $ (0.6) | ||||
| Weighted-average number of common shares - basic | 295,667 | 238,409 | 286,314 | 237,996 | ||||
| Weighted-average number of common shares - diluted | 295,667 | 238,409 | 286,314 | 237,996 | ||||
| ||||||||